Protocol Library
Each card lists peptide research notes — vial size, example research dose range, reconstitution example, frequency example, cycle length example, and risk level. All entries are educational. Not medical advice.
AICAR
high riskUsed in research contexts to study AMPK pathway activation, mitochondrial biogenesis and substrate utilization.
- Vial
- 50 mg lyophilized vial
- Dose
- Research literature ranges vary widely; educational example only.
- Freq
- Protocol-dependent in research.
- Cycle
- Short cycles in published research designs.
GHRP-2
moderate riskInvestigated for pulsatile growth hormone release via ghrelin receptor agonism.
- Vial
- 5 mg lyophilized vial
- Dose
- Commonly discussed research range: 100–300 mcg per administration.
- Freq
- 2–3x daily in research designs.
- Cycle
- 8–12 week educational example.
GHRP-6
moderate riskInvestigated for GH pulsatility and appetite signaling via ghrelin receptor agonism.
- Vial
- 5 mg lyophilized vial
- Dose
- Commonly discussed research range: 100–300 mcg per administration.
- Freq
- 2–3x daily in research designs.
- Cycle
- 8–12 week educational example.
Gonadorelin
high riskStudied for its role in the HPG axis, LH/FSH signaling research and reproductive endocrinology research models.
- Vial
- 10 mg
- Dose
- Published research literature describes microgram-range pulses (e.g. 25–200 mcg).
- Freq
- Pulsatile schedules described in research literature — frequently every few days.
- Cycle
- Highly protocol-dependent in published material.
HCG
high riskStudied for its role in LH receptor signaling research, gonadal function research models and reproductive endocrinology research.
- Vial
- 5000 IU
- Dose
- Published research literature commonly references 250–1500 IU range research scheduling.
- Freq
- Multiple times per week in published research scheduling examples.
- Cycle
- Multi-week research courses in published examples.
IGF-1 DES
high riskInvestigated for local IGF-1 receptor activity with reduced IGFBP binding.
- Vial
- 1 mg lyophilized vial
- Dose
- Commonly discussed research range: 50–100 mcg per site.
- Freq
- Site-specific in research designs.
- Cycle
- 4 week educational example.
IGF-1 LR3
high riskStudied for its role in IGF-1 pathway research, cellular growth signaling and muscle-research models.
- Vial
- 1 mg
- Dose
- Published research literature commonly cites 20–50 mcg per research day in cellular and animal study ranges.
- Freq
- Once daily in research scheduling examples.
- Cycle
- Short research cycles (commonly 4–6 weeks).
L-Carnitine
low riskStudied for its role in fatty-acid transport, mitochondrial metabolism, endurance research and metabolic energy research.
- Vial
- 200 mg/ml ampoule
- Dose
- Published research literature references a broad range; commonly cited examples include 500–2000 mg per research day.
- Freq
- Often daily in research scheduling examples.
- Cycle
- Continuous research periods are common.
MOTS-c
low riskResearched in mitochondrial and metabolic regulation contexts.
- Vial
- 10 mg
- Dose
- 5–10 mg weekly (research literature)
- Freq
- 2–3x weekly (research example)
- Cycle
- 4–8 weeks (research example)
PEG-MGF
moderate riskInvestigated for myogenic precursor activation via MGF/IGF-1Ec splice variant pathway.
- Vial
- 2 mg lyophilized vial
- Dose
- Commonly discussed research range: 200–400 mcg per administration.
- Freq
- 2–3x weekly in research designs.
- Cycle
- 4–6 week educational example.
Looking for a research supplier?
Enhanced Performance is a separate research supply platform. Visiting or purchasing is optional and not required to use PepToolbox.
Disclosure: Enhanced Performance is a separate platform connected to the owner of this website. Purchasing is optional and not required to use this tool.